Biosensors pushes boundaries of innovation for better, longer lives
Innovation, in any industry, is a strategic edge that enables a company to stand out from the competition. For medical devices expert Biosensors International Group, pushing the boundaries of science and technology is a mission with a bigger purpose - benefiting patients with better, longer lives.
Innovation, in any industry, is a strategic edge that enables a company to stand out from the competition. For medical devices expert Biosensors International Group, pushing the boundaries of science and technology is a mission with a bigger purpose - benefiting patients with better, longer lives.
Biosensors has been impacting countless lives since its founding in 1989 through its research and solutions for diverse cardiovascular, critical care and cardiac imaging applications. Among its breakthroughs is the bioresorbable coating technology for drug-eluting stents used to prevent blockages from recurring in coronary arteries after an angioplasty.
"Innovation is not just part of Biosensors' DNA," says CEO Jose Calle Gordo. "It is the lifeblood that drives our vision of touching people's lives through pioneering medical technologies."
Biosensors is among the boldest and most innovative companies in the industry. Products such as the patented BioMatrix family of drug-eluting stents have earned a significant share in key markets across Asia and Europe. Biosensors has risen as one of the top three coronary stent providers in China, one of the largest markets in the world, under its wholly owned subsidiary JW Medical Systems.
Biosensors reinvests at least 10 per cent of its revenues in research and development, with products in the pipeline including polymer-free drug-coated stents such as the BioFreedom. It is also pursuing revolutionary developments in vascular intervention and atrial fibrillation treatment through the recently acquired company Spectrum Dynamics, whose expertise in advanced functional assessment technologies is projected to boost Biosensors' portfolio and geographic reach.
Apart from expanding its presence in China, Japan and neighbouring countries, Biosensors is also eyeing mergers, acquisitions and collaborations in the United States and Europe, particularly with companies looking for credible partners with strong ties in Asia and China.
"We are thrilled to take Biosensors to the next level as a global, billion-dollar company - and with it, raise the quality of the lives that our innovations are able to touch," Calle Gordo says.